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acteristics were comparable between the two cohorts (all p-values0.05). During
median follow-up of 2.95 years, the cumulative incidence of deathwas 304 (17.72%)
among 1716 PADT patients and 94 (5.48%) among 1716 RP patients; 66 (3.85%) and 2
(0.12%) for prostate cancer specific deaths, respectively. The PADT group had
nearly 4 times higher overall mortality risk compared to those using RP (odds ratio
(OR)3.534, 95% confidence interval (CI)2.801-4.464, p0.001). Furthermore, pa-
tients who received PADT had significantly higher prostate cancer specific mortal-
ity compared to those using RP (OR30.875, 95% CI7.535-126.506, p0.001).
CONCLUSIONS: Overall mortality and prostate cancer specific mortality following
PADT were significantly higher compared to those following RP among localized
prostate cancer patients. These data do not support the use of PADT in men with
clinically localized prostate cancer.
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OBJECTIVES: Often new treatment options lack comparisons to treatment options
which already exist on themarket andwhichwere launched several years ago. Due
to such a lack of head-to-head evidence indirect treatment comparisons (ITC) are
increasingly being performed. Although ITC methods are widely accepted, the re-
sults are often interpreted with caution, probably because of their lack of external
validity proven by real clinical studies.METHODS:The first available pivotal phase-
III trials for docetaxel and erlotinib in second-line non-small cell lung cancer
(NSCLC) included best supportive care (BSC) as a comparator which allowed an ITC
of erlotinib versus docetaxel to be performed, applying the Bucher methodology.
The pemetrexed pivotal phase-III trial provided direct evidence vs docetaxel,
which subsequently allowed an ITC of erlotinib vs pemetrexed to be performed.
Later another phase-III trial was published comparing erlotinib vs pemetrexed,
which allowed the ITC of erlotinib vs docetaxel to be re-performed. This trial and a
further recently published phase-III trial directly comparing erlotinib vs docetaxel
or pemetrexed, allowed the external validation of the ITC outcomes. The overall
survival (OS) hazard ratios (HR) were used to produce ITC-OS HRs with 95% confi-
dence intervals (95%CI). RESULTS: Comparing erlotinib versus docetaxel resulted
in an ITC-OS HR of 1.25 (95%CI: 0.76-2.06, p0.381). Using these ITC results to
compare erlotinib to pemetrexed resulted in an ITC-OSHR of 1.26 (95%CI: 0.74-2.15,
p0.392). Re-performing the ITC of erlotinib versus docetaxel resulted in an ITC-OS
HR of 0.95 (95%CI: 0.71-1.28, p0.736). The head-to-head evidence validated those
findingswith anOSHR of 0.96 (95%CI: 0.77-1.21, p0.916) and 0.96 (95%CI: 0.78-1.19,
p0.730), comparing erlotinib vs pemetrexed and erlotinib versus pemetrexed or
docetaxel, respectively. CONCLUSIONS: Recently published clinical head-to-head
evidence has confirmed the appropriateness and validity of ITC findings in second-
line NSCLC.
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OBJECTIVES: In the past, interferon (IFN) has proven to be effective in extending
the survival of patients with RCC. New TT, drugs such as Sunitinib (SU), Sorafenib
(SO) and Bevacizumab (BE) have been tested against IFN. Recently, a new studywas
published, comparing a new TT, Pazopanib (PZ) versus placebo (PLA) but not inter-
feron. An important question arose about the relative efficacy of PZ versus other TT
and IFN, given that the control group used was not an active one in the PZ trial.
When head-to-head studies are lacking; an ICMA can help solving the problem of
relative efficacy. Our aim was to perform an ICMA comparing TT. METHODS: We
performed a systematic review, searching for randomized controlled trials that
compared TT against IFN or PLA, or those that compared PLA versus IFN. We
conducted an indirect comparisonmeta-analysis that used PLA as a bridge to com-
pare the different TT. The end point of interest was progression free survival (PFS).
The results are expressed as Hazard Ratio (HR), with the corresponding confidence
interval of 95% (CI). RESULTS:We found 8 randomized controlled trials that fit our
inclusion criteria. The results of the ICMA for PFSwere: PZ versus SU [HR 1.19; CI
0.37 to 3.85]; PZ versus IFN [HR0.59; CI 0.23 to 1.55]; PZ versus SO [HR0.75; CI
0.22 to 2.54]; PZ X BE [HR0.83; CI0.31 to 2.24] CONCLUSIONS: The results showed
that PZ was superior to placebo but not to IFN. The confidence intervals obtained
from the analysis were very wide precluding a definitive conclusion regarding the
relative efficacy of TT, although there was a trend to confirm the superiority of SU.
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OBJECTIVES: Study examined the pattern of chemotherapy and biologic therapy
use by line of treatment in newly diagnosed patients with colorectal cancer (CRC).
METHODS: Patients newly diagnosed with CRC between January 1, 2005 and June
31, 2009 and treated with systemic therapy were identified in a US-based admin-
istrative medical claims (i3 Innovus) database. Six months of patient history with
no prior ICD-9 diagnosis of CRC and 1-year post-index continuous enrollment was
required. Patients were followed from initial CRC diagnosis to death, disenroll-
ment, or June 31, 2010. Chemotherapy and biologic treatments over time were
analyzed to identify lines of therapy and assessed and stratified by line of therapy
(1st, 2nd, 3rd ), subgroup analysis was performed in metastatic CRC. RESULTS: Of
9876 patients, 45% received only 1st line treatment, 35% received 1st and 2nd line
treatment and 20% received 3rd line and beyond. 60% of the study patients were
identified as having metastasis either during the follow up period or at index date.
The 1st line, 43% received an oxaliplatin-based regimen, 5% received an irinotecan-
based regimen, and 46% received 5-FU alone. 2nd and 3rd line settings percentages
of patients treated with irinotecan-based regimens increased from 18% to 43%,
respectively, use of oxaliplatin-based regimens dropped from 42% to 22%, respec-
tively. The proportion of subjects who used bevacizumab doubled from 1st to 3rd
line regimen. Overall, use of cetuximab and panitumumab increased from 2% in
the 1st line to 7%, and 23%, respectively in the 2nd and 3rd  lines of treatment.
CONCLUSIONS: Despite treatment guidelines, a large proportion of patients re-
ceived 5-FUmonotherapy and capecitabine as 1st line treatment even for metaste-
ses. The use of biologics in the first line was present with use in later lines. The use
of EGFR inhibitors increased in the later lines of treatment after FOLFOX and FOL-
FIRI with or without bevacizumab.
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OBJECTIVES: Stage IV CRC patients have varying survival results from multiple
lines of treatment. The objective of this study was to evaluate in a real world
context, the impact of adding a third line of chemotherapy to a stage IV CRC
population. METHODS: The Georgia Cancer Specialist database (2005-2011) was
used. Patients with stage IV colon or rectal cancer and treated with chemotherapy
were followed from initial CRC diagnosis until death, study end or lost to follow-up.
Patientswere stratified into lines and type of protocol for treatments. Kaplan-Meier
curves were used to compare the overall survival results between lines of therapy.
RESULTS: There were 335 patients with confirmed stage IV CRC of which 35%
received one protocol, 27% two protocols, and 38% received three or more proto-
cols. The most common first line agents consisted of FOLFOX with or without
bevacizumab or FOLFIRI with or without bevacizumab. Some single agent 5FU or
5FUwith bevacizumabwas observed in first line. Themost common second agents
were the FOLFOX or FOLFIRI not given in first line. However single agent capecit-
abine, cetuximab and bevacizumab were observed. In third line similar single
agents but more panitumumab and capecitabine combinations were observed. Of
those treated with second line (45) and three or more lines (75). The median sur-
vival was no different between the patients that received second line and those
that went on to a third line (Log-Rank P0.1249). CONCLUSIONS: The addition of
adding a third line to a stage IV population that already received a second line failed
show an association to increase survival. The benefit of adding a third line may
benefit some patients and the particular combination of therapy needs to be ex-
plored in future studies.
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OBJECTIVES: To compare the economic impact from US societal perspective of
Nilotinib and Dasatinib as second-line therapies in treatment of CML patients with
Imatinib resistance or intolerance by conducting a cost-effectiveness analysis.
METHODS: A Markov simulation model was developed to estimate quality ad-
justed life years (QALYs) and expected costs using data from head-to-head com-
parative clinical trials. Costs in the model included medication cost, hospitaliza-
tion cost, physician fee, laboratory test fee, adverse events cost, and value of
waiting time and were obtained from published literature and government and
organization websites. All costs were adjusted to 2011 US dollars. The treatment
pattern was assumed to be 800mg/day for Nilotinib, or 100mg/day for Dasatinib in
the chronic phase and 140mg/day in the advancedphase. Treatmentwas evaluated
up to progression of the disease, best supportive care and up to death, operating 80
cycles of 3 months. Switching from one product to the other due to severe adverse
eventswas also considered. Sensitivity analyseswere performed to test the robust-
ness of the results. RESULTS: In the base case analysis, the total cost for treatment
with Nilotinib was $150,966, and Dasatinib was $126,672. Patients treated with
Nilotinib gained 0.57more life years, or 0.49moreQALYs, comparedwithDasatinib.
The incremental cost-effectiveness ratio (ICER) for Nilotinib therapy was $49,467/
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QALY, which indicated that Nilotinib is an advantageous treatment for CML pa-
tients in regards to treatment efficacy and cost effectiveness. One-way sensitivity
analyses indicated the results to be robust.CONCLUSIONS: Based on awillingness-
to-pay threshold of $120-$150,000/QALY, Nilotinib treatment in CML patients who
were resistant or intolerant to Imatinib is a cost-effective treatment. The results,
however, may be less applicable to high-risk patients, the elderly, children and
those eligible for bone marrow transplantation.
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OBJECTIVES: Anti-angiogenic therapy has become an integral component of treat-
ment for metastatic colorectal cancer patients. During last 10 years several studies
were conducted to test the safety and efficacy of anti-angiogenic therapies inmCRC
patients. This study reviewed the results of randomized controlled trials published
in peer-reviewed journals. METHODS: We searched the MEDLINE, and abstracts
from ECCO, ESMO and ASCO until May 2011. Studies were selected for randomized
controlled trials on targeted anti-angiogenic drugs in mCRC. Primary endpoints
reviewed were progression-free (PFS) and overall survival (OS). Response rates,
toxicity and secondary resectability were secondary endpoints. Aggregated data
were further analyzed to understand comparative safety and efficacy. RESULTS:
Until May 2011, eligible mCRC randomized clinical trials for this reviewwere avail-
able for bevacizumab (5 trials including 3101 patients) and vatalanib (2 trial includ-
ing 2033 patients). Overall, anti-angiogensis therapy formCRC shows significantOS
and PFS benefit versus comparators. The median OS and PFS benefit for regimens
containing Bevacizumab were 3 and 3.15 months, versus background chemother-
apy. The median OS and PFS benefit for vatalanib containing regimens were sta-
tistically insignificant versus background chemotherapy. CONCLUSIONS: Anti-an-
giogensis therapy with Bevacizumab for mCRC shows significant OS and PFS
benefit versus comparators.
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OBJECTIVES: The main objective of this study was to analyze the treatment pat-
terns in patients with advanced NSCLC treatment in a regional community setting:
The Georgia Cancer Specialists Network.METHODS: Patients were included in the
study if they were newly diagnosed with NSCLC as of the first practice visit and
diagnosed with stage III or stage IV disease between January 1, 2005 and June 2010.
Patients treated with chemotherapy were followed from initial NSCLC diagnosis
until death, end of study period or lost to follow up. The network’s Electronic
Medical Record (EMR)was used to identify chemotherapy agents and sequencing of
therapy. RESULTS: A total of 291 patients were identified with advanced NSCLC
(Stage IIIB or IV). Patients ranged in the age of 40 to 85 years with 125 females and
166 males. Of the 291 patients who received first line therapy, 122 (41.9%) were
treated with Carboplatin/Paclitaxel, 45 (15.5%) with Carboplatin/Paclitaxel/Bevaci-
zumab, 24 (8.2%) with Paclitaxel and 19 (6.5%) with Bevacizumab. Of the 125 pa-
tients who received second line therapy, 52(17.9%) were treated with Pemetrexed,
13 (4.5%)withDocetaxel and 8(2.7%)with Carboplatin/Gemcitabine. Themost com-
mon therapies used in the 40 patients who received third line were Pemetrexed
with 11 patients (3.8%), Docetaxel with 10 patients (3.4%), Gemcitabine with 4 pa-
tients (1.4%) andVinorelbinewith 3 patients (1%).CONCLUSIONS:Of these patients
with advanced NSCLC, 13.7% received third line therapy after previous treatment
with first and second line therapies. The majority of the agents prescribed follow
NCCN guidelines. In the third line the wide variation suggests a lack of standard of
care. Additional rigorous clinical effectiveness trials of drugs in third line treatment
are warranted to understand the benefit in NSCLC patients.
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BACKGROUND: Multiple myeloma (MM) is a B cell malignancy, of fully differenti-
ated plasma cells, and is the second most prevalent hematological malignancy
(10%) after non-Hodgkin’s lymphoma. Despite recent advances in the treatment
options for patientswithMM, it remains incurable and the vastmajority of patients
will relapse or become refractory to treatment. To date there is little information on
real world treatment outcomes for many of existing regimens. OBJECTIVES: The
objective of this multi-center observational study is to assess treatment outcomes
of patients with relapsed or refractory MM receiving either single or combination
novel therapies in real-world clinical practice. METHODS: This is a prospective,
non-interventional, cohort study that includes patients with relapsed or refractory
MM who will receive treatment for MM between 2012 and 2018 in North America
and Europe. In order to reflect real-world clinical practice patterns, patients cur-
rently enrolled in clinical trials are not eligible for this study. Patients will be fol-
lowed for up to three years, until death, enrollment in an investigational trial, or
withdrawal of consent, whichever comes first. The primary endpoints of this real
world study, include disease progression/response, progression-free survival (PFS),
overall survival (OS), secondary malignancy, and occurrence of adverse events.
Data on patient demographics, clinical characteristics, treatment patterns, health
care resources utilization, and patient-reported outcomes (e.g., EQ-5D) will also be
collected by using electronic case report throughout the study. The potential asso-
ciation between PFS and OS in this patient population will be also assessed. The
anticipated study population across multiple geographic regions is approximately
1000 patients. RESULTS: Findings from this prospective, non-interventional, mul-
tiregional studywill contribute to the knowledge of treatment patterns for relapsed
or refractory MM in real-world clinical practice.
PCN17
CHEMOTHERAPY TREATMENT AND IMPACT OF SECOND LINE CHEMOTHERAPY
ON OVERALL SURVIVAL (OS) IN METASTATIC CASTRATE RESISTANT
PROSTATE CANCER (CRPC) IN SOUTHEASTERN ONCOLOGY COMMUNITY
PRACTICE
Seal B1, Sullivan SD2, Ramsey S3, Kreilick C4, Foltz-Boklage S4, Gilmore JW5, Haslip S6,
Asche C7, Shermock KM8, Sarma S9, Sun K10
1Bayer HealthCare Pharmaceuticals, Inc., Pine Brook, NJ, USA, 2University of Washington,
Seattle, WA, USA, 3Fred Hutchinson Cancer Research Center, University of Washington, Seattle,
WA, USA, 4Bayer HealthCare, Wayne, NJ, USA, 5GA Cancer Specialists, Atlanta, GA, USA,
6Georgia Cancer Specialists, Atlanta, GA, US, Atlanta, GA, USA, 7University of Illinois, Peoria, IL,
USA, 8Analysis by Design LLC, Lutherville Timonium, MD, USA, 9Independent Consultant,
Wilmington, NC, USA, 10Sun Stat Consulting, Lutherville Timonium, MD, USA
OBJECTIVES: Prostate cancer represents the 2nd most common cause of cancer
mortality[1]. Clinical studies showed that chemotherapy (CT) had survival benefits
for Metastatic CRPC[2-6]. This study described 1st-line and 2nd-line CT and investi-
gated OS benefits of 2nd line CT using a real-world data. METHODS: The Georgia
Cancer Specialist Database containing CT,medical and pharmacy information, and
lab results for patients (PTs) with cancer (2005-2011) was used. PTs greater than 18
years old with initial stage IV CRPC who received one type CT protocol (PL), as
first-line group, and two types of PLs, as second-line group, were followed from the
first administration of CT (index date, ID) to the earlier of death or loss to follow-up.
CT use was described. Kaplan-Meier survival curve was compared between first-
line and second-line groups using log-rank test. The impact of second-line CT on
OS was further examined using multivariate Cox model with adjustment of PTs’
baseline age, race, Charlson Comorbidity Index (CCI), bisphosphonate use, and
ECOGperformance scores. RESULTS:The study included 124 PTs, with 86 (69.4%) as
first-line PTs, range in age from 18-90 (median 74 years of age), 52.4% of raceWhite,
32.3% African American, and 15.3% other or unknown race, average weight was
185LB (ranging 100-365LB), average baseline PSA 731 ng/ml (ranging 0.05-21,743ng/
ml), 107(86.3%) PTs with one or more CCI comorbid conditions, 10 (8.1%) PTs with
ECOG score as 3 or 4. 96 (77.4%). Docetaxel was used as first-line CT. Other first-line
CT drugs were: Denosumab, vinorelbine, sipuleucel-T,mitoxantrone/Prednisone,
and Cisplatin. Second-line CT drugs were: denosumab, Novantrone/Prednisone,
Cabazitaxel, and Carboplatin. Median survival was 17 months for all, 14 and 19
months for first-line and second-line PTs, respectively (P0.0654). Multivariate
COX model found a higher survival for second-line PTs (HR0.361, P0.010).
CONCLUSIONS: This study suggested that second-line CT was associated with
prolonged OS in metastatic CRPC.
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OBJECTIVES: To assess the clinical and economic burden of breast cancer patients
in the US veteran population. METHODS: A retrospective study of patients diag-
nosed with breast cancer between October 1, 2005 and September 30, 2010 was
conducted using the Veterans Health Affairs Medical SAS Datasets. Health care
resource utilization and costs were assessed in the 12-month follow-up period.
Patients’ demographic, clinical and discharge statuses were compared using Chi-
square testing and standardized differences. Mortality and survival rates were
calculated using the Kaplan and Meier method and the PROC LIFETEST procedure.
RESULTS: In patients identified with breast cancer (n11,719), the total mortality
rates in the 12-month follow-up period were 17.04% (n1,993), with 26.07%
(n1,192) for patients age 65 and over, 10.64% for age 40 to 64, and 20.22% (n90) for
patients under age 39. The medications most commonly prescribed 1 year after
breast cancer diagnosis were sodium chloride (2.43%), anastrozole (1.61%), tamox-
ifen (1.23%), dextrose (1.15%) and hydrochlorothiazide (1.07%). The most com-
monly prescribed laboratory tests were for glucose quant (3.99%), sodium (3.88%),
potassium (3.81%), creatinine (3.75%), and chloride (3.73%). The percentage of pa-
tientswho had follow-up inpatient visitswas 19.00%,which translated into $22,220
in inpatient costs per patient, while the percentage of patients who had follow-up
emergency room (ER) visits was 18.79%, which translated into $140.53 ER costs per
patient. CONCLUSIONS: The risk of developing breast cancer increases with age.
The mortality rate is relatively low for US veteran breast cancer patients between
the ages of 40 and 64, but more than doubles for patients over age 65.
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